BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25385756)

  • 1. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.
    Klein F; Nogueira L; Nishimura Y; Phad G; West AP; Halper-Stromberg A; Horwitz JA; Gazumyan A; Liu C; Eisenreich TR; Lehmann C; Fätkenheuer G; Williams C; Shingai M; Martin MA; Bjorkman PJ; Seaman MS; Zolla-Pazner S; Karlsson Hedestam GB; Nussenzweig MC
    J Exp Med; 2014 Nov; 211(12):2361-72. PubMed ID: 25385756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early antibody therapy can induce long-lasting immunity to SHIV.
    Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA
    Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
    Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
    Kent SJ; Fernandez CS; Dale CJ; Davenport MP
    Trends Microbiol; 2005 Jun; 13(6):243-6. PubMed ID: 15936652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
    Shingai M; Nishimura Y; Klein F; Mouquet H; Donau OK; Plishka R; Buckler-White A; Seaman M; Piatak M; Lifson JD; Dimitrov DS; Nussenzweig MC; Martin MA
    Nature; 2013 Nov; 503(7475):277-80. PubMed ID: 24172896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding.
    Rosenberg YJ; Jiang X; Cheever T; Coulter FJ; Pandey S; Sack M; Mao L; Urban L; Lees J; Fischer M; Smedley J; Sidener H; Stanton J; Haigwood NL
    J Virol; 2021 Aug; 95(18):e0026821. PubMed ID: 34190597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.
    Yeh WW; Rahman I; Hraber P; Coffey RT; Nevidomskyte D; Giri A; Asmal M; Miljkovic S; Daniels M; Whitney JB; Keele BF; Hahn BH; Korber BT; Shaw GM; Seaman MS; Letvin NL
    J Virol; 2010 Jun; 84(12):6018-32. PubMed ID: 20357097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.
    Nishimura Y; Martin MA
    Cell Host Microbe; 2017 Aug; 22(2):207-216. PubMed ID: 28799906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
    Pegu A; Xu L; DeMouth ME; Fabozzi G; March K; Almasri CG; Cully MD; Wang K; Yang ES; Dias J; Fennessey CM; Hataye J; Wei RR; Rao E; Casazza JP; Promsote W; Asokan M; McKee K; Schmidt SD; Chen X; Liu C; Shi W; Geng H; Foulds KE; Kao SF; Noe A; Li H; Shaw GM; Zhou T; Petrovas C; Todd JP; Keele BF; Lifson JD; Doria-Rose NA; Koup RA; Yang ZY; Nabel GJ; Mascola JR
    Cell Rep; 2022 Jan; 38(1):110199. PubMed ID: 34986348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent
    Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
    Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.
    Julg B; Liu PT; Wagh K; Fischer WM; Abbink P; Mercado NB; Whitney JB; Nkolola JP; McMahan K; Tartaglia LJ; Borducchi EN; Khatiwada S; Kamath M; LeSuer JA; Seaman MS; Schmidt SD; Mascola JR; Burton DR; Korber BT; Barouch DH
    Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for HIV Infection.
    Weiss RA
    N Engl J Med; 2014 Jan; 370(4):379-80. PubMed ID: 24450898
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.
    Amos JD; Himes JE; Armand L; Gurley TC; Martinez DR; Colvin L; Beck K; Overman RG; Liao HX; Moody MA; Permar SR
    J Virol; 2015 Sep; 89(18):9485-98. PubMed ID: 26157116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV.
    Iwamoto N; Patel B; Song K; Mason R; Bolivar-Wagers S; Bergamaschi C; Pavlakis GN; Berger E; Roederer M
    PLoS One; 2021; 16(3):e0248973. PubMed ID: 33752225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4-HIV-1 Envelope Interactions: Critical Insights for the Simian/HIV/Macaque Model.
    Sharma A; Overbaugh J
    AIDS Res Hum Retroviruses; 2018 Sep; 34(9):778-779. PubMed ID: 29886767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An HIV-1 infection-related idiotype/clonotype (1F7) is expressed on antibodies directed to envelope glycoprotein in simian immunodeficiency virus- and chimeric simian/human immunodeficiency virus-infected rhesus monkeys.
    Müller S; Margolin DH; Min G
    Hybridoma; 1997 Feb; 16(1):17-21. PubMed ID: 9085123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.